Oncotarget

Research Papers:

Impact of adjuvant hormonotherapy on radiation-induced breast fibrosis according to the individual radiosensitivity: results of a multicenter prospective French trial

Céline Bourgier, Florence Castan, Olivier Riou, Tan-Dat Nguyen, Karine Peignaux, Claire Lemanski, Jean-Léon Lagrange, Youlia Kirova, Eric Lartigau, Yazid Belkacemi, Sofia Rivera, Georges Noël, Sébastien Clippe, Françoise Mornex, Christophe Hennequin, Sophie Gourgou, Muriel Brengues, Pascal Fenoglietto, Esat Mahmut Ozsahin and David Azria _

PDF  |  HTML  |  How to cite

Oncotarget. 2018; 9:15757-15765. https://doi.org/10.18632/oncotarget.24606

Metrics: PDF 1315 views  |   HTML 2920 views  |   ?  


Abstract

Céline Bourgier1, Florence Castan1, Olivier Riou1, Tan-Dat Nguyen2, Karine Peignaux3, Claire Lemanski1, Jean-Léon Lagrange4, Youlia Kirova5, Eric Lartigau6, Yazid Belkacemi4, Sofia Rivera7, Georges Noël8, Sébastien Clippe9, Françoise Mornex10, Christophe Hennequin11, Sophie Gourgou1, Muriel Brengues1, Pascal Fenoglietto1, Esat Mahmut Ozsahin12 and David Azria1

1Institute de Recherche en Cancérologie de Montpellier, Inserm U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier, Montpellier, France

2Institute Jean Godinot, Reims, France

3Centre GF Leclerc, Dijon, France

4AP-HP Henri Mondor, Créteil, France

5Institute Curie, Paris, France

6Centre Oscar Lambret, Lille, France

7Gustave Roussy, Villejuif, France

8Centre Paul Strauss, Strasbourg, France

9Centre Marie Curie, Valence, France

10Centre Hospitalier Lyon Sud, Pierre Bénite, France

11AP-HP Saint-Louis, Paris, France

12Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

Correspondence to:

David Azria, email: [email protected]

Keywords: radiotherapy; breast cancer; hormonotherapy; individual radiosensitivity; late effects

Received: November 30, 2017     Accepted: February 25, 2018     Epub: March 02, 2018     Published: March 20, 2018

ABSTRACT

Background: To evaluate risk of severe breast fibrosis occurrence in patients treated by breast-conserving surgery, adjuvant radiotherapy and hormonotherapy (HT) according to individual radiosensitivity (RILA assay).

Results: HT– and RILAhigh were the two independent factors associated with improved breast-fibrosis free survival (BFFS). BFFS rate at 36 months was lower in patients with RILAlow and HT+ than in patients with RILAhigh and HT– (75.8% and 100%, respectively; p = 0.004, hazard ratio 5.84 [95% confidence interval (CI) 1.8–19.1]). Conversely, BFFS at 36 months was comparable in patients with RILAhigh and HT+ and in patients with RILAlow and HT– (89.8% and 93.5%, respectively; p = 0.39, hazard ratio 1.7 [95% CI 0.51–5.65]), showing that these two parameters influenced independently the occurrence of severe breast fibrosis. BFFS rate was not affected by the HT type (tamoxifen or aromatase inhibitor) and timing (concomitant or sequential with radiotherapy).

Conclusions: HT and RILA score independently influenced BFFS rate at 36 months. Patients with RILAhigh and HT– presented an excellent BFFS at 36 months (100%).

Materials and methods: Breast Fibrosis-Free Survival (BFFS) rate was assessed relative to RILA categories and to adjuvant HT use (HT+ and HT–, respectively) in a prospective multicentre study (NCT00893035) which enrolled 502 breast cancer patients (456 evaluable patients). Breast fibrosis was recorded according to CTCAE v3.0 grading scale; RILA score was defined according to two categories (<12%: RILAlow; ≥12%: RILAhigh).


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 24606